Moti Hacham

Moti Hacham currently serves as Chief Financial Officer at OncoHost since January 2021 and as a Board Member and Chief Executive Officer of Spero Biopharma since June 2019, where Spero Biopharma is focused on developing Ladostigil, a drug aimed at preventing the progression from Mild Cognitive Impairment to Alzheimer's disease. Previously, Moti held the position of Co-Chief Executive Officer at NevaBio Ltd. and Chief Financial & Operation Officer at Avraham Pharmaceuticals and Curetech, engaging in various business development and operational activities. Moti also served as CEO of Clal Life Sciences, managing a pharmaceutical incubator, and as VP Operations at Polyheal Ltd., overseeing company operations and financial management. Moti holds a Bachelor's degree in Economics from Tel Aviv University and a Bachelor of Laws (LLB) from Bar-Ilan University.